Abstracts tagged "clinical trial"

Abstract Number: 1197 • ACR Convergence 2023
Efficacy and Safety of a Single Intra-Articular Injection of MM-II, a Novel Suspension of Large, Empty, Multilamellar Liposomes, in People with Painful Knee OA: Results of a 26-Week, Phase 2b, Placebo-Controlled, Double-Blind, Randomized Trial
Schnitzer Thomas¹, Helene Rovsing², Edith Lau³, Sidsel Boll⁴, Ballari Brahmachari⁵, Richard Chou⁶, Tarini Joshi⁵, Roni Wechsler⁷, Siu-Long Yao⁵, Sveta Weiner⁵, Asger Bihlet⁸ and Philip Conaghan⁹, ¹Northwestern University Feinberg School of Medicine, Chicago, IL, ²Sanos Clinic, Gandrup, Denmark, ³Hong Kong Center for Clinical Research, Hong Kong, China, ⁴Sanos Clinic, Vejle, Denmark, ⁵Sun Pharmaceutical Industries, Inc., Princeton, NJ, ⁶Jacobs School of Medicine and Biomedical Sciences, University of Buffalo, Buffalo, NY, ⁷Moebius Medical, Tel Aviv, Israel, ⁸NBCD, Soeborg, Denmark, ⁹University of Leeds, Leeds, United Kingdom
Background/Purpose: Safe and effective therapies are needed for OA pain. MM-II, a novel suspension of large, empty, multilamellar liposomes composed of dimyristoylphosphatidylcholine and dipalmitoylphosphatidylcholine, effectively…
Abstract Number: 1434 • ACR Convergence 2023
Long-Term Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 148-Week Results from the KEEPsAKE 2 Trial
Andrew Östör¹, Filip Van den Bosch², Kim A Papp³, Cecilia Asnal⁴, Ricardo Blanco⁵, Jacob Aelion⁶, Vassilis Stakias⁷, Thomas Iyile⁷, Kyle Carter⁷, Ahmed Soliman⁷, Leonidas Drogaris⁷, Michael Chen⁷, Byron Padilla⁷ and Alan Kivitz⁸, ¹Monash University & Emeritus Research; Australian National University, Melbourne, Australia, ²Department of Internal Medicine and Pediatrics, Ghent University and VIB Center for Inflammation Research, Ghent, Belgium, ³Alliance Clinical Research and Probity Medical Research, Waterloo, and University of Toronto, Toronto, ON, Canada, ⁴Hospital Alemán, Buenos Aires, Argentina, ⁵Rheumatology Department, Immunopathology Group, Hospital Universitario Marqués de Valdecilla-IDIVAL, Santander, Spain, ⁶West Tennessee Research Institute, Jackson, TN, ⁷AbbVie, Inc., North Chicago, IL, ⁸Altoona Center for Clinical Research, Duncansville, PA
Background/Purpose: PsA is a chronic systemic inflammatory disease that affects 30% of patients diagnosed with psoriasis, with a clinical burden that includes dactylitis, enthesitis, cutaneous…
Abstract Number: 1614 • ACR Convergence 2023
Therapy Combining Millimeter Wave-based Neuromodulation with Coaching for the Improvement in Quality of Life of Patients with Fibromyalgia: A Prospective, Multicenter, Randomized, Controlled Trial
Caroline Maindet¹, Anne Dumolard², Mélanie Veloso², Mario Barmaki³, Rodrigue Deleens⁴, Raphaël Gonon-Demoulian⁵, Alberta Lorenzi-Pernot⁶, Mireille Michel-Cherqui⁷, Alain Serrie⁸, Stanislas Velliet⁹ and Jean-Luc Bosson², ¹University Hospital Grenoble Alpes, Grenoble, France, ²Grenoble Alpes University Hospital, Grenoble, France, ³Médipôle Lyon Villeurbanne, Lyon, France, ⁴Rouen University Hospital, Rouen, France, ⁵Montpellier University Hospital, Montpellier, France, ⁶Neurology private practice, Mornant, France, ⁷Foch hospital, Suresnes, France, ⁸Paris University Hospital, Paris, Guinea, ⁹Valenciennes hospital, Valenciennes, France
Background/Purpose: Fibromyalgia is a chronic syndrome with symptoms of moderate to severe intensity, including diffuse pain, fatigue, sleep disturbance, and cognitive impairment. While first-line recommendation…
Abstract Number: 2055 • ACR Convergence 2023
A Randomized Controlled Trial of Two Hepatitis a Vaccine Doses Among Adolescents with Juvenile Idiopathic Arthritis and Crohn’s Disease on Immunosuppressive Therapy: A Pilot Study
Racheal Githumbi¹, Susan Kuhn¹, Carla Osiowy², Jennifer DeBruyn¹, Marvin Fritzler¹, Nicole Johnson¹, Otto G Vanderkooi¹ and Heinrike Schmeling¹, ¹University of Calgary, Calgary, AB, Canada, ²National Microbiology Laboratory, Public Health Agency of Canada, Winnepig, MB, Canada
Background/Purpose: Juvenile idiopathic arthritis (JIA) and Crohn's disease (CD) are now controlled using immunosuppressive medications. However, disease control comes at the risk of increased infection.…
Abstract Number: 2330 • ACR Convergence 2023
Disease-Related Outcomes of Cognitive Behavioral Therapy in Randomized Control Trial for Youth with Childhood-onset SLE: A Secondary Analysis
Natoshia Cunningham¹, Michelle Adler¹, Ashley Danguecan², Mallet Reid¹, Samantha Ely³, Mathew Reeves⁴, Lawrence Ng², Paris Moaf², Tala El Tal⁵, Sarah Mossad², Luana Flores Pereira², Deborah Levy², Linda Hiraki², Jennifer Stinson², Sara Ahola Kohut², khalid abulaban⁶, Elizabeth Kessler⁷, Stacy Allen⁸, Tamar Rubinstein⁹, Evin Rothschild¹⁰, Natalie Rosenwasser¹¹, Kabita Nanda¹², Susan Canny¹³, Emily Smitherman¹⁴, Livie Huie¹⁵, James Birmingham¹⁶, Ekemini Ogbu¹⁷, Hermine Brunner¹⁸, Dhriti Sharma¹⁹, Allison Thompson²⁰, Janel Thompson²¹, Miranda Moyer²⁰, Emily Nguyen²⁰, Angela Chapson²⁰ and Andrea Knight², ¹Michigan State University, Grand Rapids, MI, ²The Hospital for Sick Children, Toronto, ON, Canada, ³Michigan State University, Wayne State University, Grand Rapids, MI, ⁴Michigan State University, East Lansing, MI, ⁵Children's Hospital of Eastern Ontario (CHEO), Ottawa, ON, Canada, ⁶Helen DeVos Children's Hospital, Ada, MI, ⁷Spectrum Health, Grand Rapids, MI, ⁸Helen DeVos Children's Hospital, Caledonia, MI, ⁹Albert Einstein College of Medicine, Children's Hospital at Montefiore, White Plains, NY, ¹⁰Albert Einstein Medical Center, Children's Hospital at Montefiore, Bronx, NY, ¹¹Seattle Children's Hospital, Seattle, WA, ¹²Seattle Children's Hospital/University of Washington, Seattle, WA, ¹³Seattle Children's Hospital/University of Washington, Seattle, WA, ¹⁴University of Alabama at Birmingham, Birmingham, AL, ¹⁵University of Alabama at Birmingham, Gardendale, AL, ¹⁶Self, Ada, MI, ¹⁷Cincinnati Children's Hospital Medical Center, University of Cincinnati School of Medicine, Johns Hopkins University, Cincinnati, OH, ¹⁸Cincinnati Children's Hospital Medical Center, Division of Rheumatology, Cincinnati, OH, ¹⁹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²⁰Patient Co-Investigative Team, n/a, ²¹Patient Co-Investigative Team, Revere, PA
Background/Purpose: Childhood-onset systemic lupus erythematosus (cSLE) is associated with symptoms such as fatigue, pain, and depressive symptoms that contribute to poor health-related quality of life.…
Abstract Number: 2548 • ACR Convergence 2023
Low Uveitis Rates in Patients with Axial Spondyloarthritis Treated with Bimekizumab: Pooled Results from Phase 2b/3 Trials
Martin Rudwaleit¹, Matthew A. Brown², Floris Van Gaalen³, Nigil Haroon⁴, Lianne Gensler⁵, Carmen Fleurinck⁶, Alexander Marten⁷, Ute Massow⁸, Natasha De Peyrecave⁹, Thomas Vaux¹⁰, Katy White¹⁰, Atul Deodhar¹¹ and Irene van der Horst-Bruinsma¹², ¹University of Bielefeld, Klinikum Bielefeld, Bielefeld, Germany, ²Genomics England, London, United Kingdom, ³Leiden University Medical Center, Department of Rheumatology, Leiden, Netherlands, ⁴University of Toronto, University Health Network, Schroeder Arthritis Institute, Department of Medicine/Rheumatology, Toronto, ON, Canada, ⁵University of California San Francisco, Department of Medicine, Division of Rheumatology, San Francisco, CA, ⁶UCB Pharma, Oosterzele, Belgium, ⁷UCB Pharma, Monheim, Germany, ⁸UCB Pharma, Monheim am Rhein, Germany, ⁹UCB Pharma, Brussels, Belgium, ¹⁰UCB Pharma, Slough, United Kingdom, ¹¹Division of Arthritis and Rheumatic Disease, Oregon Health & Science University, Portland, OR, ¹²Radboud University Medical Centre, Department of Rheumatology, Nijmegen, Netherlands
Background/Purpose: Acute anterior uveitis ('uveitis'), or 'iritis', is a common extra-musculoskeletal manifestation among patients (pts) with axial spondyloarthritis (axSpA).1 IL-17 has been implicated in the…
Abstract Number: 0459 • ACR Convergence 2023
Upadacitinib Monotherapy versus Methotrexate in Patients with Rheumatoid Arthritis: Efficacy and Safety Through 5 Years in the SELECT-EARLY Randomized Controlled Trial
Ronald van Vollenhoven¹, Vibeke Strand², Tsutomu Takeuchi³, Nilmo Chávez⁴, Pablo Mannucci Walter⁵, Attul Singhal⁶, Jerzy Swierkot⁷, Nasser Khan⁸, Xianwei Bu⁹, Yihan Li⁹, Sara Penn⁹, Heidi Camp⁹ and Jacob Aelion¹⁰, ¹Amsterdam University Medical Centers, Amsterdam, Netherlands, ²Stanford University, Portola Valley, CA, ³Keio University School of Medicine and Saitama Medical University, Tokyo, Japan, ⁴Instituto Guatemalteco de Seguridad Social, Guatemala, Guatemala, ⁵Aprillus Asistencia e Investigación, Buenos Aires, Argentina, ⁶Southwest Rheumatology Research Group, Dallas, TX, ⁷Department of Rheumatology and Internal Medicine, Wrocław Medical Hospital, Wrocław, Poland, ⁸Pharmacovigilance and Patient Safety, AbbVie, Inc., North Chicago, IL, ⁹AbbVie, Inc., North Chicago, IL, ¹⁰West Tennessee Research Institute, Jackson, TN
Background/Purpose: To evaluate the efficacy and safety of upadacitinib (UPA) monotherapy vs MTX monotherapy over 5 yrs among MTX-naïve patients with moderately to severely active…
Abstract Number: 0817 • ACR Convergence 2023
Comparative Effectiveness of Yoga and Strengthening Exercise for Treating Knee OsteoArthritis: A Randomised Controlled Trial (YOGA Trial)
Bedru Abafita¹, Ambrish Singh¹, Dawn Aitken¹, Steffany Moonaz², Andrew J Palmer¹, Leigh Blizzard¹, Changhai Ding¹, Stan Drummen¹, Graeme Jones³, Kim Bennell⁴ and Benny Samuel Antony¹, ¹Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia, ²Department of Clinical and Health Services Research, Southern California University of Health Sciences, Whittier, CA, ³Menzies Institute for Medical Research, University of Tasmania, Melbourne, Australia, ⁴University of Melbourne, Melbourne, Australia
Background/Purpose: There is uncertainty about the best type of exercise to optimise outcomes for people with knee osteoarthritis (OA). Strengthening exercise is commonly recommended. However,…
Abstract Number: 1265 • ACR Convergence 2023
Changes in the Endocannabinoid Tone in Rheumatoid Arthritis and Osteoarthritis – Discovery of a Novel Target for the Treatment of Pain and Inflammation?
Jost Klawitter¹, Andrew Clauw¹, Jennifer Seifert¹, Jelena Klawitter¹, Bridget Tompson¹, Cristina Sempio¹, Uwe Christians¹ and Larry Moreland², ¹University of Colorado Anschutz Medical Campus, Aurora, CO, ²University of Colorado, Denver, CO

Background/Purpose: Inflammation is a complicated physiological process that results in a variety of disorders. Several inflammatory mediators are produced during this process, which is responsible…
Abstract Number: 1435 • ACR Convergence 2023
Long-Term Efficacy and Safety of Risankizumab for CsDMARD-IR Patients with Active Psoriatic Arthritis: 148-Week Results from the KEEPsAKE 1 Trial
Lars Erik¹, Mauro Keiserman², Kim A Papp³, Leslie McCasland⁴, Douglas White⁵, Vassilis Stakias⁶, Thomas Iyile⁶, Kyle Carter⁶, Ahmed Soliman⁶, Leonidas Drogaris⁶, Michael Chen⁶, Byron Padilla⁶ and Frank Behrens⁷, ¹Bispebjerg-Frederiksberg Hospital, Vedbæk, Denmark, ²Pontifical Catholic University School of Medicine, Porto Alegre, Brazil, ³Alliance Clinical Research and Probity Medical Research, Waterloo, and University of Toronto, Toronto, ON, Canada, ⁴Arthritis and Rheumatism Associates, Jonesboro, AR, ⁵Waikato Clinical School, University of Auckland, Hamilton, New Zealand, ⁶AbbVie, Inc., North Chicago, IL, ⁷Goethe-University & Fraunhofer ITMP, Frankfurt, Germany
Background/Purpose: Risankizumab (RZB), a humanized immunoglobulin G1 monoclonal antibody that inhibits interleukin-23 by targeting its p19 subunit with high affinity and specificity, is approved for…
Abstract Number: 1633 • ACR Convergence 2023
Dose Dependent Modulation of a B Cell Protein Signature by Ianalumab in Patients with Sjögren’s Disease
Stephanie Finzel¹, Andrea Grioni², Benjamin A Fisher³, Athena S Papas⁴, Alexandre Avrameas², Danny Tuckwell², Jonas Zierer², Celine Rauld², Valeria De Luca², Enrico Ferrero², Andre Nogueira da Costa², Rainer Hillenbrand², Isabelle Isnardi² and Wolfgang Hueber², ¹Department of Rheumatology and Clinical Immunology, University Medical Center Freiburg, University of Freiburg, Freiburg, Germany, ²Novartis Pharma AG, Basel, Switzerland, ³University of Birmingham, Birmingham, United Kingdom, ⁴Division of Oral Medicine, Tufts School of Dental Medicine, Boston, MA
Background/Purpose: Ianalumab (VAY736) is an afuscosylated monoclonal antibody targeting the B cell activating factor receptor (BAFFR) that depletes B cells via enhanced antibody dependent cellular…
Abstract Number: 2063 • ACR Convergence 2023
Training to Increase Minority Enrollment in Lupus Clinical Trials with CommunitY Engagement (TIMELY): Assessing Behavioral Predictors of Clinical Trial Referrals Among Healthcare Providers
Saira Sheikh¹, Tessa Englund¹, Andrew Simkus², Nicole Wanty³, Annie McNeill⁴, Kristen Holtz⁴, Tenesha Hood⁵, Starla Blanks⁶, Maria Allen⁷ and Allen Anandarajah⁷, ¹University of North Carolina at Chapel Hill, Chapel Hill, NC, ²KDH Research & Communication, Asheville, NC, ³KDH Research & Communication, Marietta, GA, ⁴KDH Research & Communication, Atlanta, GA, ⁵ACR, Atlanta, GA, ⁶American College of Rheumatology, Atlanta, GA, ⁷University of Rochester Medical Center, Rochester, NY
Background/Purpose: The aim of this study is to assess outcomes among healthcare providers in the American College of Rheumatology's (ACR) Training to Increase Minority Enrollment…
Abstract Number: 2332 • ACR Convergence 2023
Dapirolizumab Pegol Efficacy by Subgroups in Patients with SLE: A Post Hoc Analysis of Phase 2b Clinical Trial Data
Anca Askanase¹, Christian Stach², Claire Brittain³, George Stojan⁴ and Richard Furie⁵, ¹Columbia University Medical Center, New York, NY, ²UCB Pharma, Monheim am Rheim, Germany, ³UCB Pharma, Slough, United Kingdom, ⁴UCB, Baltimore, MD, ⁵Northwell Health, Manhasset, NY
Background/Purpose: Systemic lupus erythematosus (SLE) clinical trials are challenged by high standard of care plus placebo (SOC+PBO) response rates.1 Previous post hoc analyses of the…
Abstract Number: 2549 • ACR Convergence 2023
Effect of Ixekizumab Treatment on MRI Structural Lesions in the Sacroiliac Joints of Patients with Radiographic Axial Spondyloarthritis; A Post-hoc Analysis of a Placebo and Active Controlled RCT
Walter P. Maksymowych¹, Robert Lambert², Eswar Krishnan³, Baojin Zhu³, Rebecca Bolce³ and Mikkel Østergaard⁴, ¹University of Alberta, Edmonton, AB, Canada, ²Department of Radiology and Diagnostic Imaging, University of Alberta, Edmonton, AB, Canada, ³Eli Lilly and Company, Indianapolis, IN, ⁴Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet; University of Copenhagen, Copenhagen, Denmark
Background/Purpose: The effect of Ixekizumab (IXE) on structural lesions in the sacroiliac joints (SIJ) of patients (pts) with radiographic Axial Spondylarthritis (r-axSpA) assessed by magnetic…
Abstract Number: 0480 • ACR Convergence 2023
Non-random Sampling in Rheumatology Randomized Controlled Trials: Evidence of Concerning Trial Conduct?
Victoria Le¹, Mats Junek², Mike Putman³, Maximilian Casey¹, Kenrick Manswell¹, Jay Goldsher¹, Elizabeth Nettleton¹, Desh Nepal¹ and Sanket Shah¹, ¹Medical College of Wisconsin, Milwaukee, WI, ²McMaster University, Hamilton, ON, Canada, ³Division of Rheumatology, Medical College of Wisconsin, Milwaukee, WI
Background/Purpose: Non-random sampling of baseline variables in randomized controlled trials (RCTs) may be due unintentional errors, stratified randomization strategies, or data fabrication. Prior studies have…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].